Google Übersetzer
About
Ascletis Pharma Inc (HK:1672) — investor relations, events, news, and company updates on 6ix.
Latest News
Today
Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions
Apr 27 2026
Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes
Apr 7 2026
Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Mar 10 2026
Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity
Feb 10 2026
Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development
Recent Videos
Ascletis Pharma Inc. 2025 annual report
Apr 01, 2026
Ascletis Pharma (1672) | Alphabet boosts debt sales to $32 billion as tech races to fund AI | 11-2
Feb 11, 2026
𝗔𝗦𝗖𝗟𝗘𝗧𝗜𝗦 (𝟭𝟲𝟳𝟮.𝗛𝗞) 𝗕𝗥𝗘𝗔𝗞𝗧𝗛𝗥𝗢𝗨𝗚𝗛: 𝗡𝗘𝗪 𝗢𝗥𝗔𝗟 𝗧𝗥𝗜𝗣𝗟𝗘-𝗔𝗚𝗢𝗡𝗜𝗦𝗧 𝗖𝗢𝗨𝗟𝗗 𝗗𝗜𝗦𝗥𝗨𝗣𝗧 𝗢𝗕𝗘𝗦𝗜𝗧𝗬 𝗠𝗔𝗥𝗞𝗘𝗧
Dec 02, 2025
Ascletis Picks ASC37 as Lead Oral Triple Agonist – Clinical News Update
Dec 01, 2025